Meeting
2023 ASCO Annual Meeting
Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.
Authors
Alexander I. Spira
Virginia Cancer Specialists, US Oncology Network, Fairfax, VA
Alexander I. Spira , Beata Korytowsky , Sara Gao , Renard Dubois , Thomas Wilson , Andrew Osterland , Junxin Shi , Paul R. Conkling
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6629)
DOI
10.1200/JCO.2023.41.16_suppl.6629
Abstract #
6629
Poster Bd #
121
Abstract Disclosures
Similar Posters
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada.
First Author: Dimas Yusuf
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.
First Author: Daniel M. Geynisman
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A real-world analysis of non-small cell lung cancer patients treated with pembrolizumab or pembrolizumab in combination with pemetrexed and platinum.
First Author: Himani Agg
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah